CJC-1295 (no DAC) / Mod GRF(1-29)
Also known as: Mod GRF 1-29, CJC-1295 without DAC, Tetrasubstituted GRF
CJC-1295 (no DAC) / Mod GRF(1-29), also called Mod GRF 1-29 or CJC-1295 without DAC, is a short-acting GHRH analog in the Growth Hormone Secretagogue class. This is modified GRF(1-29), a GHRH analog carrying four amino-acid substitutions that protect it from dipeptidyl peptidase-4 cleavage but without the drug affinity complex group that lets the DAC version bind albumin.
For research use only.
Key Facts
- CAS
- 863288-34-0
- Molecular Weight (MW)
- ≈3368 g/mol
- Half-life
- Not measured in humans; commonly estimated at about 30 minutes (vs 6–8 days for the DAC form)
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Sep 26, 2026
- Reviewed
- Aug 30, 2026
- Targets
- GHRH receptor
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 17
- Listed offers
- 22
- Median price per mg
- $8.06/mg
- Typical $7.34–$10.00/mg
Research summary
Modified GRF(1-29), a growth hormone-releasing hormone analog carrying four amino-acid substitutions that resist enzymatic breakdown but without the drug affinity complex group that makes the DAC version long-acting. It is short-acting — its half-life is commonly estimated at about thirty minutes, although no published human study has measured it — rather than producing the multi-day elevation of DAC-CJC, and the two are pharmacologically distinct despite the shared name. Not FDA-approved. Prohibited in sport under WADA class S2.
Peptide Library's CJC-1295 (no DAC) / Mod GRF(1-29) profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
CJC-1295 (no DAC) / Mod GRF(1-29) dosage: no established human dose
CJC-1295 without DAC, also sold as Mod GRF(1-29), has no established human dosage. No trial of it is registered and no human study of this specific molecule is indexed. The two published CJC-1295 human studies used the DAC form, a deliberately longer-acting molecule, and their dosing does not transfer. The closest molecule with published human dosing is sermorelin, GHRH(1-29), from which this one differs by four amino acid substitutions.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: CJC-1295 without DAC is a tetra-substituted GHRH(1-29) analogue, the substitutions being intended to resist enzymatic degradation without the albumin-binding Drug Affinity Complex. It is a short-acting growth hormone releasing hormone analogue in the same family as sermorelin. No human study of this specific molecule is indexed, so there is no human dose, route or interval established for it, and dosing for the DAC form or for sermorelin is not carried over here.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-09-05 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Human study of CJC-1295 with DAC, a different moleculeClinical trial · Human pharmacology study of the DAC analogue, not this moleculeStudied an analog, not CJC-1295 (no DAC) / Mod GRF(1-29) itself | Healthy adults | 30 or 60 mcg/kg of the DAC form | Subcutaneous | — | — | Growth hormone and IGF-1 secretion | Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. |
| Human dose-response for GHRH(1-29)-NH2, the parent analogueClinical trial · Human pharmacology study of GHRH(1-29)-NH2, a related but distinct analogueStudied an analog, not CJC-1295 (no DAC) / Mod GRF(1-29) itself | Human subjects in a dose-response protocol | 0.25 mcg/kg produced significant GH release; maximal at 1-2 mcg/kg intravenously | Intravenous and intranasal | — | — | Growth hormone release and pharmacokinetics | Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion. Acta Paediatr Suppl. 1993. |
Where sources disagree
- Protocols of 100 mcg once to three times daily are widely published for CJC-1295 no-DAC. No human study of this molecule is indexed and no trial is registered, so no primary source for those figures could be identified.
- The name CJC-1295 is used for two different molecules. Human data exists only for the DAC form; vendors and reference sites routinely cite the 2006 studies on pages selling the no-DAC version. Both rows on this site now say which molecule each study actually used.
- CJC-1295 no-DAC, Mod GRF(1-29) and CJC-1295 DAC are frequently treated as interchangeable. They differ in half-life by orders of magnitude, which is precisely what determines a dosing interval.
Reconstitution
Common research vial sizes: 2 mg, 5 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 2 mg | 2 mL | 1 mg/mL | 10 mcg per 0.01 mL |
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Timing Notes
- Shorter t½ than DAC variant.
Sequence & molecular data
| Molecular formula | C152H252N44O42 |
|---|---|
| Molecular weight | ≈3368 g/mol |
| CAS number | 863288-34-0 |
| Half-life | Not measured in humans; commonly estimated at about 30 minutes (vs 6–8 days for the DAC form) |
| Appearance | White lyophilized powder (acetate) |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This is modified GRF(1-29), a GHRH analog carrying four amino-acid substitutions that protect it from dipeptidyl peptidase-4 cleavage but without the drug affinity complex group that lets the DAC version bind albumin. It binds the pituitary GHRH receptor, raising cyclic AMP and stimulating growth hormone release, but its half-life remains short — commonly estimated at about thirty minutes rather than days, although no published human pharmacokinetic study has measured it. The practical consequence is a brief, discrete GH pulse resembling physiological release, in contrast to the sustained elevation produced by the DAC form. These are pharmacologically distinct compounds despite the shared name.
Origin
Tetrasubstituted GHRH(1–29).
Targets
Studies
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (class-level evidence)
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (class-level evidence)
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (class-level evidence)
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (class-level evidence)
Regulatory & research status
CJC-1295 (no DAC) / Mod GRF(1-29) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
Benefits
CJC-1295 (no DAC) / Mod GRF(1-29) side effects
CJC-1295 (no DAC) / Mod GRF(1-29) has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Flushing
- Transient GH-related edema
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
CJC-1295 (no DAC) / Mod GRF(1-29): frequently asked questions
What is CJC-1295 (no DAC) / Mod GRF(1-29)?
Modified GRF(1-29), a growth hormone-releasing hormone analog carrying four amino-acid substitutions that resist enzymatic breakdown but without the drug affinity complex group that makes the DAC version long-acting. It is short-acting — its half-life is commonly estimated at about thirty minutes, although no published human study has measured it — rather than producing the multi-day elevation of DAC-CJC, and the two are pharmacologically distinct despite the shared name. Not FDA-approved. Prohibited in sport under WADA class S2.
How does CJC-1295 (no DAC) / Mod GRF(1-29) work?
This is modified GRF(1-29), a GHRH analog carrying four amino-acid substitutions that protect it from dipeptidyl peptidase-4 cleavage but without the drug affinity complex group that lets the DAC version bind albumin. It binds the pituitary GHRH receptor, raising cyclic AMP and stimulating growth hormone release, but its half-life remains short — commonly estimated at about thirty minutes rather than days, although no published human pharmacokinetic study has measured it.
Is CJC-1295 (no DAC) / Mod GRF(1-29) FDA approved?
No. CJC-1295 (no DAC) / Mod GRF(1-29) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of CJC-1295 (no DAC) / Mod GRF(1-29)?
No published human pharmacokinetic study has measured the half-life of CJC-1295 without DAC. It is commonly estimated at about 30 minutes, compared with 5.8–8.1 days measured for the DAC form (Teichman et al., 2006). Half-life describes how long the compound persists in circulation, not how long any effect lasts.
Is CJC-1295 (no DAC) / Mod GRF(1-29) banned in sport?
CJC-1295 (no DAC) / Mod GRF(1-29) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to CJC-1295 (no DAC) / Mod GRF(1-29)?
Compounds most often compared with CJC-1295 (no DAC) / Mod GRF(1-29) include Sermorelin, Tesamorelin, CJC-1295 and CJC-1295 (no DAC) + Ipamorelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- Class-level evidence — Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — J Clin Endocrinol Metab, 2006External reference
- Class-level evidence — Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026External reference
- Class-level evidence — Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026External reference
- Class-level evidence — Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports Med, 2026External reference
Related research, comparisons & guides
- Ipamorelin vs Tesamorelin: Two Receptors, One Approved Drug
- Tesamorelin vs CJC-1295: Same Receptor, Different Clock
- CJC-1295 and Ipamorelin: Why the Pairing Exists and What the Vial Math Looks Like
- Peptide stacks: combinations by research goalStacks
- Peptide dosage chart: dose, route and frequencyCategory
- Peptide calculator with the CJC-1295 (no DAC) / Mod GRF(1-29) preset
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 26, 2026 · Version 3
This CJC-1295 (no DAC) / Mod GRF(1-29) profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track CJC-1295 (no DAC) / Mod GRF(1-29) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →